PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
9748239-4	1998	In primary rat and human hepatocytes fenofibric acid, respectively, decreased and increased apoA-I mRNA levels.	fenofibric acid	37-52	apolipoprotein A1	Homo sapiens	92-98
9353271-9	1997	In the hepatocyte cell lines AML-12 or Fa 32, fenofibric acid, but not BRL 49653, induced FATP and ACS mRNA levels, whereas in the 3T3-L1 preadipocyte cell line, the PPARgamma ligand induced FATP and ACS mRNA levels quicker than fenofibric acid.	fenofibric acid	46-61	solute carrier family 27 (fatty acid transporter), member 1	Mus musculus	90-94
9747588-0	1998	Release of inflammatory mediators (PGE2, IL-6) by fenofibric acid-photosensitized human keratinocytes and fibroblasts.	fenofibric acid	50-65	interleukin 6	Homo sapiens	41-45
9618412-1	1998	The NADP+-dependent dehydrogenase activity of a predominant isoenzyme of human liver 3alpha-hydroxysteroid dehydrogenase was activated by antihyperlipidemic drugs, such as bezafibrate and clinofibrate, and by clofibric acid and fenofibric acid (active metabolites of clofibrate and fenofibrate, respectively).	fenofibric acid	228-243	aldo-keto reductase family 1 member C3	Homo sapiens	85-120
9353271-9	1997	In the hepatocyte cell lines AML-12 or Fa 32, fenofibric acid, but not BRL 49653, induced FATP and ACS mRNA levels, whereas in the 3T3-L1 preadipocyte cell line, the PPARgamma ligand induced FATP and ACS mRNA levels quicker than fenofibric acid.	fenofibric acid	46-61	acyl-CoA synthetase long-chain family member 1	Mus musculus	99-102
9353271-9	1997	In the hepatocyte cell lines AML-12 or Fa 32, fenofibric acid, but not BRL 49653, induced FATP and ACS mRNA levels, whereas in the 3T3-L1 preadipocyte cell line, the PPARgamma ligand induced FATP and ACS mRNA levels quicker than fenofibric acid.	fenofibric acid	46-61	peroxisome proliferator activated receptor gamma	Mus musculus	166-175
9353271-9	1997	In the hepatocyte cell lines AML-12 or Fa 32, fenofibric acid, but not BRL 49653, induced FATP and ACS mRNA levels, whereas in the 3T3-L1 preadipocyte cell line, the PPARgamma ligand induced FATP and ACS mRNA levels quicker than fenofibric acid.	fenofibric acid	46-61	solute carrier family 27 (fatty acid transporter), member 1	Mus musculus	191-195
9353271-9	1997	In the hepatocyte cell lines AML-12 or Fa 32, fenofibric acid, but not BRL 49653, induced FATP and ACS mRNA levels, whereas in the 3T3-L1 preadipocyte cell line, the PPARgamma ligand induced FATP and ACS mRNA levels quicker than fenofibric acid.	fenofibric acid	46-61	acyl-CoA synthetase long-chain family member 1	Mus musculus	200-203
7657063-9	1995	Fenofibric acid concomitantly induced LAH activity and peroxisomal PCOA in rat hepatocytes.	fenofibric acid	0-15	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	38-41
9174678-0	1997	Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia.	fenofibric acid	28-43	apolipoprotein B	Homo sapiens	148-164
9174678-6	1997	The high correlation between plasma fenofibric acid levels and its effect on beta lipoprotein changes might reflect the effect of fenofibrate on the catabolism of plasma LDL by the LDL receptor, since that type of relationship is typical of drugs which directly influence the target compartment without an effect on intermediary steps of metabolism.	fenofibric acid	36-51	low density lipoprotein receptor	Homo sapiens	181-193
7642600-4	1995	In primary rat hepatocytes and Fa-32 hepatoma cells C-ACS mRNA increased after treatment with fenofibric acid, alpha-bromopalmitate, tetradecylthioacetic acid, or alpha-linolenic acid.	fenofibric acid	94-109	acyl-CoA synthetase long-chain family member 1	Rattus norvegicus	54-57
7642600-6	1995	Transient transfections showed a 3.4-, 2.3-, and 2.2-fold induction of C-ACS promoter activity after fenofibric acid, alpha-bromopalmitate, and tetradecylthioacetic acid, respectively.	fenofibric acid	101-116	acyl-CoA synthetase long-chain family member 1	Rattus norvegicus	73-76
7635967-3	1995	This increase in plasma apo A-II was due to a direct effect on hepatic apo A-II production, since fenofibric acid induced apo A-II mRNA levels to 450 and 250% of control levels in primary cultures of human hepatocytes and in human hepatoblastoma HepG2 cells respectively.	fenofibric acid	98-113	NLR family pyrin domain containing 3	Homo sapiens	75-79
8895578-4	1996	In the hepatocyte cell line AML-12, fenofibric acid, but not BRL 49653, induced LPL mRNA, whereas in 3T3-L1 preadipocytes, the PPARgamma ligand induced LPL mRNA levels much quicker and to a higher extent than fenofibric acid.	fenofibric acid	36-51	lipoprotein lipase	Rattus norvegicus	80-83
8895578-4	1996	In the hepatocyte cell line AML-12, fenofibric acid, but not BRL 49653, induced LPL mRNA, whereas in 3T3-L1 preadipocytes, the PPARgamma ligand induced LPL mRNA levels much quicker and to a higher extent than fenofibric acid.	fenofibric acid	36-51	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	127-136
8895578-4	1996	In the hepatocyte cell line AML-12, fenofibric acid, but not BRL 49653, induced LPL mRNA, whereas in 3T3-L1 preadipocytes, the PPARgamma ligand induced LPL mRNA levels much quicker and to a higher extent than fenofibric acid.	fenofibric acid	36-51	lipoprotein lipase	Rattus norvegicus	152-155
8895578-4	1996	In the hepatocyte cell line AML-12, fenofibric acid, but not BRL 49653, induced LPL mRNA, whereas in 3T3-L1 preadipocytes, the PPARgamma ligand induced LPL mRNA levels much quicker and to a higher extent than fenofibric acid.	fenofibric acid	209-224	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	127-136
8647932-12	1996	Treatment of human primary hepatocytes with fenofibric acid (500 microM) provoked an 83 and 50% increase in apo A-I secretion and mRNA levels, respectively, supporting that a direct action of fibrates on liver human apo A-I production leads to the observed increase in plasma apo A4 and HDL-cholesterol.	fenofibric acid	44-59	apolipoprotein A1	Homo sapiens	108-115
8647932-12	1996	Treatment of human primary hepatocytes with fenofibric acid (500 microM) provoked an 83 and 50% increase in apo A-I secretion and mRNA levels, respectively, supporting that a direct action of fibrates on liver human apo A-I production leads to the observed increase in plasma apo A4 and HDL-cholesterol.	fenofibric acid	44-59	apolipoprotein A1	Homo sapiens	216-223
7635967-3	1995	This increase in plasma apo A-II was due to a direct effect on hepatic apo A-II production, since fenofibric acid induced apo A-II mRNA levels to 450 and 250% of control levels in primary cultures of human hepatocytes and in human hepatoblastoma HepG2 cells respectively.	fenofibric acid	98-113	apolipoprotein A2	Homo sapiens	24-32
7635967-3	1995	This increase in plasma apo A-II was due to a direct effect on hepatic apo A-II production, since fenofibric acid induced apo A-II mRNA levels to 450 and 250% of control levels in primary cultures of human hepatocytes and in human hepatoblastoma HepG2 cells respectively.	fenofibric acid	98-113	NLR family pyrin domain containing 3	Homo sapiens	28-32
8297388-0	1994	Fenofibric acid modulates the human apolipoprotein A-IV gene expression in HepG2 cells.	fenofibric acid	0-15	apolipoprotein A4	Homo sapiens	36-55
8297388-1	1994	The influence of the hypolipidemic drug, fenofibric acid, on the regulation of apolipoprotein A-IV (apoA-IV) gene expression was investigated in two human cell lines, HepG2 and Caco-2.	fenofibric acid	41-56	apolipoprotein A4	Homo sapiens	79-98
8297388-1	1994	The influence of the hypolipidemic drug, fenofibric acid, on the regulation of apolipoprotein A-IV (apoA-IV) gene expression was investigated in two human cell lines, HepG2 and Caco-2.	fenofibric acid	41-56	apolipoprotein A4	Homo sapiens	100-107
8297388-2	1994	As shown in the present report, fenofibric acid induces a strong dose-dependent increase of the apoA-IV mRNA level in HepG2 cells, while other apolipoproteins mRNA levels are only slightly modified.	fenofibric acid	32-47	apolipoprotein A4	Homo sapiens	96-103
8297388-4	1994	The increase of the apoA-IV mRNA level could be correlated with a clear enhancement of DNase I hypersensitive sites in the 5" flanking region of the gene in nuclei of HepG2 cells treated with fenofibric acid.	fenofibric acid	192-207	apolipoprotein A4	Homo sapiens	20-27
8297388-5	1994	Thus, fenofibric acid may act by facilitating the interaction of nuclear regulatory proteins with the DNA in the control regions of the apoA-IV gene.	fenofibric acid	6-21	apolipoprotein A4	Homo sapiens	136-143
6888156-7	1983	Fenofibric acid is a hypolipidemic drug which inhibits 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMGCoA reductase) activity, the limiting step of endogenous cholesterol synthesis.	fenofibric acid	0-15	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	105-121
2885979-2	1987	Clofibrate, clofibric acid, fenofibric acid and dulofibrate, which are mainly hypotriglyceridaemic, increased the content in cytochromes P-450 (77-185% over control), and especially cytochrome P-452-dependent lauric acid 12-hydroxylation (5.6- to 8.4-fold increase).	fenofibric acid	28-43	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	182-198
26297615-0	2015	Beneficial effects of fenofibric acid on overexpression of extracellular matrix components, COX-2, and impairment of endothelial permeability associated with diabetic retinopathy.	fenofibric acid	22-37	prostaglandin-endoperoxide synthase 2	Homo sapiens	92-97
34332233-2	2021	The 2-propanoic acid derivative 10a and the 2-butanoic acid congener 10i showed the best overall PPARalpha agonistic activity showing Emax% values of 50.80 and 90.55%, respectively, and EC50 values of 8.9 and 25.0 muM, respectively, compared to fenofibric acid with Emax = 100% and EC50 = 23.22 muM, respectively.	fenofibric acid	245-260	peroxisome proliferator activated receptor alpha	Homo sapiens	97-106
34421587-4	2021	Fenofibric acid also destabilized the receptor-binding domain (RBD) of the viral spike protein and inhibited RBD binding to ACE2 in enzyme-linked immunosorbent assay (ELISA) and whole cell-binding assays.	fenofibric acid	0-15	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	81-86
34421587-4	2021	Fenofibric acid also destabilized the receptor-binding domain (RBD) of the viral spike protein and inhibited RBD binding to ACE2 in enzyme-linked immunosorbent assay (ELISA) and whole cell-binding assays.	fenofibric acid	0-15	angiotensin converting enzyme 2	Homo sapiens	124-128
35563117-0	2022	Functional and Structural Insights into Human PPARalpha/delta/gamma Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.	fenofibric acid	104-119	peroxisome proliferator activated receptor alpha	Homo sapiens	46-61
35563117-3	2022	Because PPARalpha/delta/gamma share considerable amino acid identity and three-dimensional structures, especially in ligand-binding domains (LBDs), clinically approved fibrates, such as bezafibrate, fenofibric acid, and pemafibrate, could also act on PPARdelta/gamma when used as anti-NAFLD drugs.	fenofibric acid	199-214	peroxisome proliferator activated receptor alpha	Homo sapiens	8-17
35563117-7	2022	We herein reveal five novel high-resolution structures of PPARdelta/gamma-bezafibrate, PPARgamma-fenofibric acid, and PPARdelta/gamma-pemafibrate, thereby providing the molecular basis for their application beyond dyslipidemia treatment.	fenofibric acid	97-112	peroxisome proliferator activated receptor gamma	Homo sapiens	87-96
35213965-8	2022	Finally, the FDA-approved drugs bilastine, bromfenac, and fenofibric acid are suggested as potential and lead FFA1 agonists.	fenofibric acid	58-73	free fatty acid receptor 1	Homo sapiens	110-114
31233254-7	2019	Fenofibric acid, an active metabolite of fenofibrate, inhibited Wnt signaling and mitochondrial function in EPCs and decreased EPC numbers in Vldlr -/- mice.	fenofibric acid	0-15	very low density lipoprotein receptor	Mus musculus	142-147
33107777-10	2020	Conclusions: Modified lipoproteins elicited outer BRB injury in an experimental model, which was reduced by fenofibric acid through a PPARalpha-independent, AMPK-mediated mechanism.	fenofibric acid	108-123	peroxisome proliferator activated receptor alpha	Homo sapiens	134-143
33107777-10	2020	Conclusions: Modified lipoproteins elicited outer BRB injury in an experimental model, which was reduced by fenofibric acid through a PPARalpha-independent, AMPK-mediated mechanism.	fenofibric acid	108-123	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	157-161
29621036-4	2018	Surprisingly, gemcabene showed no or little PPAR-alpha transactivation compared with reference agonists, which showed concentration-dependent transactivation against human PPAR-alpha of 2.4- to 30-fold (fenofibric acid), 17-fold (GW590735), and 2.3- to 25-fold (WY-14643).	fenofibric acid	203-218	peroxisome proliferator activated receptor alpha	Homo sapiens	172-182
31078963-3	2019	However, fenofibrate does not cross the blood brain barrier and is quickly processed by blood and tissue esterases to form the PPARalpha agonist fenofibric acid, which is practically ineffective effective in triggering cancer cell death.	fenofibric acid	145-160	peroxisome proliferator activated receptor alpha	Mus musculus	127-136
30765336-5	2019	In vitro, fenofibric acid (FFA) rescued high glucose-induced (25 mmol/L) impairment of endothelial cell migration, tubulogenesis, and survival in a PPARalpha-independent manner.	fenofibric acid	10-25	peroxisome proliferator activated receptor alpha	Mus musculus	148-157
30765336-5	2019	In vitro, fenofibric acid (FFA) rescued high glucose-induced (25 mmol/L) impairment of endothelial cell migration, tubulogenesis, and survival in a PPARalpha-independent manner.	fenofibric acid	27-30	peroxisome proliferator activated receptor alpha	Mus musculus	148-157
29238904-3	2018	The test compounds fenofibric acid, fenofibrate, and the standard drug diclofenac exhibited binding energies of - 9.0, - 7.2, and - 8.0 kcal mol-1, respectively, against COX-2 and - 7.2, - 7.0, and - 6.5 kcal mol-1, respectively, against COX-1.	fenofibric acid	19-34	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	170-175
29238904-3	2018	The test compounds fenofibric acid, fenofibrate, and the standard drug diclofenac exhibited binding energies of - 9.0, - 7.2, and - 8.0 kcal mol-1, respectively, against COX-2 and - 7.2, - 7.0, and - 6.5 kcal mol-1, respectively, against COX-1.	fenofibric acid	19-34	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	238-243
25432415-9	2015	Fenofibric acid led to a +23% (CI +10 to +36, p = 0.001) increase in PCSK9; the addition of niacin resulted in a subsequent -17% decrease (CI -19 to -5, p = 0.004).	fenofibric acid	0-15	proprotein convertase subtilisin/kexin type 9	Homo sapiens	69-74
29182629-11	2017	Pioglitazone (PPARgamma-specific), tesaglitazar (PPARgamma/alpha-specific), and fenofibric acid (PPARalpha-specific) all provided >90% protection from gentamicin toxicity by regulation of overlapping subsets of genes controlling ROS detoxification.	fenofibric acid	80-95	peroxisome proliferator activated receptor alpha	Mus musculus	97-106
28980001-1	2017	Purpose: This study was designed to evaluate effects of fenofibric acid (Feno-FA), a peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist, on ocular neovascularization (NV) in models recapitulating neovascular age-related macular degeneration (AMD), and to explore whether the effects are PPARalpha dependent.	fenofibric acid	56-71	peroxisome proliferator activated receptor alpha	Mus musculus	85-133
28980001-1	2017	Purpose: This study was designed to evaluate effects of fenofibric acid (Feno-FA), a peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist, on ocular neovascularization (NV) in models recapitulating neovascular age-related macular degeneration (AMD), and to explore whether the effects are PPARalpha dependent.	fenofibric acid	56-71	peroxisome proliferator activated receptor alpha	Mus musculus	135-144
28980001-1	2017	Purpose: This study was designed to evaluate effects of fenofibric acid (Feno-FA), a peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist, on ocular neovascularization (NV) in models recapitulating neovascular age-related macular degeneration (AMD), and to explore whether the effects are PPARalpha dependent.	fenofibric acid	56-71	peroxisome proliferator activated receptor alpha	Mus musculus	305-314
28980001-1	2017	Purpose: This study was designed to evaluate effects of fenofibric acid (Feno-FA), a peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist, on ocular neovascularization (NV) in models recapitulating neovascular age-related macular degeneration (AMD), and to explore whether the effects are PPARalpha dependent.	fenofibric acid	73-80	peroxisome proliferator activated receptor alpha	Mus musculus	135-144
28980001-1	2017	Purpose: This study was designed to evaluate effects of fenofibric acid (Feno-FA), a peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist, on ocular neovascularization (NV) in models recapitulating neovascular age-related macular degeneration (AMD), and to explore whether the effects are PPARalpha dependent.	fenofibric acid	73-80	peroxisome proliferator activated receptor alpha	Mus musculus	305-314
28980001-8	2017	Results: Feno-FA significantly reduced vascular leakage in CNV rats and Vldlr-/- mice, reduced CNV volume in laser-induced CNV rats, and suppressed SRNV and IRNV in Vldlr-/- mice.	fenofibric acid	9-16	very low density lipoprotein receptor	Rattus norvegicus	72-80
28980001-8	2017	Results: Feno-FA significantly reduced vascular leakage in CNV rats and Vldlr-/- mice, reduced CNV volume in laser-induced CNV rats, and suppressed SRNV and IRNV in Vldlr-/- mice.	fenofibric acid	9-16	very low density lipoprotein receptor	Mus musculus	165-173
28980001-9	2017	In addition, Feno-FA downregulated the expression of inflammatory factors, including VEGF, TNF-alpha, and intercellular cell adhesion molecule-1 (ICAM-1), in the eyecups of CNV rats and decreased adherent retinal leukocytes in Vldlr-/- mice.	fenofibric acid	13-20	vascular endothelial growth factor A	Rattus norvegicus	85-89
28980001-9	2017	In addition, Feno-FA downregulated the expression of inflammatory factors, including VEGF, TNF-alpha, and intercellular cell adhesion molecule-1 (ICAM-1), in the eyecups of CNV rats and decreased adherent retinal leukocytes in Vldlr-/- mice.	fenofibric acid	13-20	tumor necrosis factor	Rattus norvegicus	91-100
28980001-9	2017	In addition, Feno-FA downregulated the expression of inflammatory factors, including VEGF, TNF-alpha, and intercellular cell adhesion molecule-1 (ICAM-1), in the eyecups of CNV rats and decreased adherent retinal leukocytes in Vldlr-/- mice.	fenofibric acid	13-20	intercellular adhesion molecule 1	Rattus norvegicus	106-144
28980001-9	2017	In addition, Feno-FA downregulated the expression of inflammatory factors, including VEGF, TNF-alpha, and intercellular cell adhesion molecule-1 (ICAM-1), in the eyecups of CNV rats and decreased adherent retinal leukocytes in Vldlr-/- mice.	fenofibric acid	13-20	intercellular adhesion molecule 1	Rattus norvegicus	146-152
28980001-9	2017	In addition, Feno-FA downregulated the expression of inflammatory factors, including VEGF, TNF-alpha, and intercellular cell adhesion molecule-1 (ICAM-1), in the eyecups of CNV rats and decreased adherent retinal leukocytes in Vldlr-/- mice.	fenofibric acid	13-20	very low density lipoprotein receptor	Rattus norvegicus	227-232
28980001-10	2017	Furthermore, Pparalpha-/- mice developed more severe CNV compared with WT mice, and PPARalpha knockout abolished the beneficial effects of Feno-FA on CNV.	fenofibric acid	139-146	peroxisome proliferator activated receptor alpha	Mus musculus	84-93
28980001-11	2017	Conclusions: Feno-FA has therapeutic effects on ocular NV in models recapitulating neovascular AMD through a PPARalpha-dependent mechanism.	fenofibric acid	13-20	peroxisome proliferator activated receptor alpha	Mus musculus	109-118
26203185-6	2015	This apparent discrepancy can be explained in several ways, one of them is that the beta-glucuronidase-resistent fenofibric acid isomers are responsible.	fenofibric acid	113-128	glucuronidase beta	Homo sapiens	84-102
27618583-0	2017	C/EBP-beta Is Differentially Affected by PPARalpha Agonists Fenofibric Acid and GW7647, But Does Not Change Apolipoprotein A-I Production During ER-Stress and Inflammation.	fenofibric acid	60-75	CCAAT enhancer binding protein beta	Homo sapiens	0-10
27618583-0	2017	C/EBP-beta Is Differentially Affected by PPARalpha Agonists Fenofibric Acid and GW7647, But Does Not Change Apolipoprotein A-I Production During ER-Stress and Inflammation.	fenofibric acid	60-75	peroxisome proliferator activated receptor alpha	Homo sapiens	41-50
27599626-6	2016	Of nine carbonyl-reducing enzymes (CREs) tested, CBR1 exhibited the greatest activity for fenofibric acid reduction (CLint = 85.975 mul/mg protein/min).	fenofibric acid	90-105	carbonyl reductase 1	Homo sapiens	49-53
27599626-7	2016	CBR1 predominantly formed (-)-enantiomers of reduced fenofibric acid similar to liver cytosol and in accordance with the in vivo data.	fenofibric acid	53-68	carbonyl reductase 1	Homo sapiens	0-4
27599626-8	2016	AKR1C1, AKR1C2, AKR1C3 and AKR1B1 were also identified as reductases of fenofibric acid but are expected to play only a minor role in fenofibric acid metabolism.	fenofibric acid	72-87	aldo-keto reductase family 1 member C1	Homo sapiens	0-6
27599626-8	2016	AKR1C1, AKR1C2, AKR1C3 and AKR1B1 were also identified as reductases of fenofibric acid but are expected to play only a minor role in fenofibric acid metabolism.	fenofibric acid	72-87	aldo-keto reductase family 1 member C2	Homo sapiens	8-14
27599626-8	2016	AKR1C1, AKR1C2, AKR1C3 and AKR1B1 were also identified as reductases of fenofibric acid but are expected to play only a minor role in fenofibric acid metabolism.	fenofibric acid	72-87	aldo-keto reductase family 1 member C3	Homo sapiens	16-22
27599626-8	2016	AKR1C1, AKR1C2, AKR1C3 and AKR1B1 were also identified as reductases of fenofibric acid but are expected to play only a minor role in fenofibric acid metabolism.	fenofibric acid	72-87	aldo-keto reductase family 1 member B	Homo sapiens	27-33
27599626-8	2016	AKR1C1, AKR1C2, AKR1C3 and AKR1B1 were also identified as reductases of fenofibric acid but are expected to play only a minor role in fenofibric acid metabolism.	fenofibric acid	134-149	aldo-keto reductase family 1 member C1	Homo sapiens	0-6
27599626-8	2016	AKR1C1, AKR1C2, AKR1C3 and AKR1B1 were also identified as reductases of fenofibric acid but are expected to play only a minor role in fenofibric acid metabolism.	fenofibric acid	134-149	aldo-keto reductase family 1 member C2	Homo sapiens	8-14
27599626-8	2016	AKR1C1, AKR1C2, AKR1C3 and AKR1B1 were also identified as reductases of fenofibric acid but are expected to play only a minor role in fenofibric acid metabolism.	fenofibric acid	134-149	aldo-keto reductase family 1 member C3	Homo sapiens	16-22
27599626-8	2016	AKR1C1, AKR1C2, AKR1C3 and AKR1B1 were also identified as reductases of fenofibric acid but are expected to play only a minor role in fenofibric acid metabolism.	fenofibric acid	134-149	aldo-keto reductase family 1 member B	Homo sapiens	27-33
25516156-9	2015	Fenofibric acid, the active metabolite of the PPARalpha agonist fenofibrate, was detected in liver, plasma, and brain after 1 or 8 days of oral treatment.	fenofibric acid	0-15	peroxisome proliferator activated receptor alpha	Mus musculus	46-55
24704626-0	2014	Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia.	fenofibric acid	100-115	lipoprotein lipase	Homo sapiens	5-8
23633496-0	2013	Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy.	fenofibric acid	97-112	apolipoprotein A5	Homo sapiens	5-10
24845641-5	2014	Mice with OIR were injected intraperitoneally with the PPARalpha agonist fenofibric acid (FA) or with adenovirus expressing PPARalpha (Ad-PPARalpha).	fenofibric acid	73-88	peroxisome proliferator activated receptor alpha	Mus musculus	55-64
24845641-12	2014	Fenofibric acid decreased retinal HIF-1alpha and SDF-1 levels as well as serum SDF-1 levels in the OIR model.	fenofibric acid	0-15	chemokine (C-X-C motif) ligand 12	Mus musculus	49-54
24845641-12	2014	Fenofibric acid decreased retinal HIF-1alpha and SDF-1 levels as well as serum SDF-1 levels in the OIR model.	fenofibric acid	0-15	chemokine (C-X-C motif) ligand 12	Mus musculus	79-84
24825105-10	2014	Nuclear hypoxia-inducible factor-alpha (HIF-1alpha) and nicotine adenine dinucleotide phosphate oxidase-4 (Nox 4) were increased in OIR retinas and downregulated by Feno-FA in WT but not in PPARalpha(-/-) mice.	fenofibric acid	165-172	hypoxia inducible factor 1, alpha subunit	Mus musculus	40-50
24825105-10	2014	Nuclear hypoxia-inducible factor-alpha (HIF-1alpha) and nicotine adenine dinucleotide phosphate oxidase-4 (Nox 4) were increased in OIR retinas and downregulated by Feno-FA in WT but not in PPARalpha(-/-) mice.	fenofibric acid	165-172	NADPH oxidase 4	Mus musculus	56-105
24825105-10	2014	Nuclear hypoxia-inducible factor-alpha (HIF-1alpha) and nicotine adenine dinucleotide phosphate oxidase-4 (Nox 4) were increased in OIR retinas and downregulated by Feno-FA in WT but not in PPARalpha(-/-) mice.	fenofibric acid	165-172	NADPH oxidase 4	Mus musculus	107-112
24825105-10	2014	Nuclear hypoxia-inducible factor-alpha (HIF-1alpha) and nicotine adenine dinucleotide phosphate oxidase-4 (Nox 4) were increased in OIR retinas and downregulated by Feno-FA in WT but not in PPARalpha(-/-) mice.	fenofibric acid	165-172	peroxisome proliferator activated receptor alpha	Mus musculus	190-199
23633496-3	2013	The APOA5 gene region was sequenced in 1,612 individuals with mixed dyslipidemia in a randomized trial of fenofibric acid alone and in combination with statins.	fenofibric acid	106-121	apolipoprotein A5	Homo sapiens	4-9
23633496-5	2013	Rare APOA5 promoter region variants were associated with decreased HDL-C and apoA-I levels in response to fenofibric acid therapy; rare missense variants were associated with increased TG response to combination therapy.	fenofibric acid	106-121	apolipoprotein A5	Homo sapiens	5-10
23633496-5	2013	Rare APOA5 promoter region variants were associated with decreased HDL-C and apoA-I levels in response to fenofibric acid therapy; rare missense variants were associated with increased TG response to combination therapy.	fenofibric acid	106-121	apolipoprotein A1	Homo sapiens	77-83
22896670-0	2012	Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.	fenofibric acid	103-118	retinoid X receptor alpha	Homo sapiens	32-36
22896670-0	2012	Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.	fenofibric acid	103-118	angiopoietin like 3	Homo sapiens	46-53
22896670-0	2012	Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.	fenofibric acid	103-118	apolipoprotein B	Homo sapiens	75-79
22896670-3	2012	We sought to identify gene-gene interactions that affect ApoB response to statin-fenofibric acid therapy in the mixed dyslipidemia population.	fenofibric acid	81-96	apolipoprotein B	Homo sapiens	57-61
21888945-6	2012	When administered in combination with a PPARalpha agonist (fenofibric acid) but not with a PPARgamma agonist (pioglitazone), BMP-4 enhanced osteoblast differentiation through the activity of PPARalpha.	fenofibric acid	59-74	bone morphogenetic protein 4	Mus musculus	125-130
22622962-2	2012	A trial is under way to evaluate the effect of once-daily fenofibric acid or placebo on carotid intima-media thickness (CIMT) progression in patients with controlled low-density lipoprotein cholesterol (LDL-C) levels achieved through atorvastatin treatment, but with high TG and low HDL-C levels.	fenofibric acid	58-73	CIMT	Homo sapiens	120-124
22622962-6	2012	CONCLUSIONS: This trial is the first to examine the effect of fenofibric acid on CIMT and the first CIMT trial to select patients with controlled LDL-C and elevated TG and low HDL-C as inclusion criteria.	fenofibric acid	62-77	CIMT	Homo sapiens	81-85
22445869-4	2012	Males treated with propranolol, fenofibric acid and with mixtures, showed an increase of vitellogenin immunostaining, compared with the control.	fenofibric acid	32-47	vitellogenin	Danio rerio	89-101
22236405-0	2012	LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.	fenofibric acid	81-96	lipoprotein lipase	Homo sapiens	0-3
22236405-0	2012	LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.	fenofibric acid	81-96	apolipoprotein C3	Homo sapiens	25-33
22236405-3	2012	We sought to identify single nucleotide polymorphisms (SNPs) associated with apoC-III level response to combination therapy with statins and fenofibric acid (FA) in individuals with mixed dyslipidemia.	fenofibric acid	141-156	apolipoprotein C3	Homo sapiens	77-85
22663953-13	2012	Second competition of fenofibric acid for UGT1A9 an enzyme implicated in conjugation of MPA may have decreased its metabolism.	fenofibric acid	22-37	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	42-48
21888945-6	2012	When administered in combination with a PPARalpha agonist (fenofibric acid) but not with a PPARgamma agonist (pioglitazone), BMP-4 enhanced osteoblast differentiation through the activity of PPARalpha.	fenofibric acid	59-74	peroxisome proliferator activated receptor alpha	Mus musculus	191-200
21715349-0	2011	Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability.	fenofibric acid	0-15	fibronectin 1	Homo sapiens	24-35
21889769-0	2011	Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.	fenofibric acid	91-106	apolipoprotein A5	Homo sapiens	16-21
21369818-0	2011	Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1beta by suppressing AMP-activated protein kinase (AMPK) activation.	fenofibric acid	0-15	interleukin 1 beta	Homo sapiens	74-91
21369818-0	2011	Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1beta by suppressing AMP-activated protein kinase (AMPK) activation.	fenofibric acid	0-15	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	107-135
21369818-0	2011	Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1beta by suppressing AMP-activated protein kinase (AMPK) activation.	fenofibric acid	0-15	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	137-141
21369818-8	2011	RESULTS: Treatment of ARPE-19 cells with fenofibric acid significantly reduced the increment of permeability and the breakdown of the ARPE-19 cell monolayer induced by D-glucose, 25 mmol/l, and IL-1beta, 10 ng/ml, in a dose-dependent manner.	fenofibric acid	41-56	interleukin 1 beta	Homo sapiens	194-202
21369818-10	2011	Fenofibric acid prevented the activation of AMPK induced by IL-1beta and the hyperpermeability induced by IL-1beta was blocked by silencing AMPK.	fenofibric acid	0-15	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	44-48
21369818-10	2011	Fenofibric acid prevented the activation of AMPK induced by IL-1beta and the hyperpermeability induced by IL-1beta was blocked by silencing AMPK.	fenofibric acid	0-15	interleukin 1 beta	Homo sapiens	60-68
21369818-10	2011	Fenofibric acid prevented the activation of AMPK induced by IL-1beta and the hyperpermeability induced by IL-1beta was blocked by silencing AMPK.	fenofibric acid	0-15	interleukin 1 beta	Homo sapiens	106-114
21369818-10	2011	Fenofibric acid prevented the activation of AMPK induced by IL-1beta and the hyperpermeability induced by IL-1beta was blocked by silencing AMPK.	fenofibric acid	0-15	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	140-144
21369818-11	2011	CONCLUSIONS/INTERPRETATION: Disruption of RPE induced by IL-1beta is prevented by fenofibric acid through its ability to suppress AMPK activation.	fenofibric acid	82-97	interleukin 1 beta	Homo sapiens	57-65
21369818-11	2011	CONCLUSIONS/INTERPRETATION: Disruption of RPE induced by IL-1beta is prevented by fenofibric acid through its ability to suppress AMPK activation.	fenofibric acid	82-97	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	130-134
21416219-4	2011	RESULTS: Addition of fenofibric acid to moderate-dose statin for 52 weeks resulted in significant (P < 0.001) improvements in non-high-density lipoprotein cholesterol (non-HDL-C; -9.0%), ApoB (-9.8%), HDL-C (14.9%), and triglycerides (-37.6%) compared with baseline.	fenofibric acid	21-36	apolipoprotein B	Homo sapiens	190-194
21438793-6	2011	Among all patients, optimal levels of ApoB, HDL-C, TG, and the combined target of LDL-C + non-HDL-C + ApoB + HDL-C + TG were achieved by higher percentage of patients treated with fenofibric acid + low- and moderate-dose statin versus corresponding dose-statin monotherapies (p <= 0.04 for all comparisons).	fenofibric acid	180-195	apolipoprotein B	Homo sapiens	38-42
21438793-6	2011	Among all patients, optimal levels of ApoB, HDL-C, TG, and the combined target of LDL-C + non-HDL-C + ApoB + HDL-C + TG were achieved by higher percentage of patients treated with fenofibric acid + low- and moderate-dose statin versus corresponding dose-statin monotherapies (p <= 0.04 for all comparisons).	fenofibric acid	180-195	apolipoprotein B	Homo sapiens	102-106
21438793-8	2011	CONCLUSIONS: In patients with mixed dyslipidemia, short-term treatment with the combination of fenofibric acid and low- or moderate-dose statin resulted in comparable or more patients achieving individual targets of non-HDL-C, ApoB, HDL-C, and TG, and combined targets for these parameters and LDL-C, compared with corresponding-dose statin monotherapy.	fenofibric acid	95-110	apolipoprotein B	Homo sapiens	227-231
21416219-6	2011	CONCLUSIONS: The addition of fenofibric acid to moderate-dose statin in patients whose LDL-C was optimal but whose triglycerides remained >200 mg/dL led to additional improvements in non-HDL-C, ApoB, HDL-C, and triglycerides that resulted in greater proportions of patients attaining optimal levels of the individual parameters as well as simultaneously achieving optimal levels of these parameters and LDL-C.	fenofibric acid	29-44	apolipoprotein B	Homo sapiens	197-201
20953684-5	2010	RESULTS: Treatment with rosuvastatin + fenofibric acid resulted in statistically significant greater improvements in HDL-C (23.0% vs. 12.4%; P < 0.001) and TG (-40.3% vs. -17.5%; P < 0.001), compared with rosuvastatin monotherapy; and LDL-C (-28.7% vs. -4.1%; P < 0.001), compared with fenofibric acid monotherapy.	fenofibric acid	39-54	component of oligomeric golgi complex 2	Homo sapiens	241-246
21060209-5	2011	The TPA-induced expression of PDGF-B mRNA and PDGF-BB protein levels in culture media was significantly decreased by treatment with PPARalpha activators, Wy14643 and fenofibric acid, in a dose-dependent manner.	fenofibric acid	166-181	platelet derived growth factor subunit B	Homo sapiens	30-36
21060209-5	2011	The TPA-induced expression of PDGF-B mRNA and PDGF-BB protein levels in culture media was significantly decreased by treatment with PPARalpha activators, Wy14643 and fenofibric acid, in a dose-dependent manner.	fenofibric acid	166-181	peroxisome proliferator activated receptor alpha	Homo sapiens	132-141
20136164-10	2010	Compared with low- or moderate-dose statin, fenofibric acid + low- or moderate-dose statin resulted in over 5-fold higher percentages of patients achieving optimal levels of LDL-C, non-HDL-C, apolipoprotein B, HDL-C, and triglycerides simultaneously.	fenofibric acid	44-59	apolipoprotein B	Homo sapiens	192-208
20614230-4	2010	Furthermore, we also demonstrated that the masking of carboxyl group in fenofibric acid via esterification or amidation was required for the inhibitory potencies of fenofibric acid derivatives against 11beta-HSD1.	fenofibric acid	72-87	hydroxysteroid 11-beta dehydrogenase 1	Homo sapiens	201-212
20614230-4	2010	Furthermore, we also demonstrated that the masking of carboxyl group in fenofibric acid via esterification or amidation was required for the inhibitory potencies of fenofibric acid derivatives against 11beta-HSD1.	fenofibric acid	165-180	hydroxysteroid 11-beta dehydrogenase 1	Homo sapiens	201-212
20146263-11	2010	Fenofibric acid-dependent regulation of caveolin-1 was analyzed.	fenofibric acid	0-15	caveolin 1	Rattus norvegicus	40-50
20146263-16	2010	Caveolin-1 expression is strongly repressed by the peroxisome proliferator-activated receptor-alpha agonist fenofibric acid.	fenofibric acid	108-123	caveolin 1	Rattus norvegicus	0-10
20146263-16	2010	Caveolin-1 expression is strongly repressed by the peroxisome proliferator-activated receptor-alpha agonist fenofibric acid.	fenofibric acid	108-123	peroxisome proliferator activated receptor alpha	Rattus norvegicus	51-99
19782138-5	2010	The addition of a PPAR alpha specific ligand (fenofibric acid, GW7647 or GW590735) to the growth media significantly stabilized the PPAR alpha LBD structure and enhanced the expression of soluble protein.	fenofibric acid	46-61	peroxisome proliferator activated receptor alpha	Homo sapiens	18-28
19782138-5	2010	The addition of a PPAR alpha specific ligand (fenofibric acid, GW7647 or GW590735) to the growth media significantly stabilized the PPAR alpha LBD structure and enhanced the expression of soluble protein.	fenofibric acid	46-61	peroxisome proliferator activated receptor alpha	Homo sapiens	132-142
20524719-7	2010	Significant (p < or = 0.04 for all comparisons) improvements in non-HDL-C, ApoB, HDL-C, TG, and hsCRP levels were also observed with each of the rosuvastatin/fenofibric acid doses as compared with simvastatin 40 mg. Treatment-related AEs and discontinuations due to AEs were similar across groups.	fenofibric acid	161-176	apolipoprotein B	Homo sapiens	78-82
19702658-9	2009	Treatment of N2a cells with flurbiprofen or fenofibric acid selectively enhanced Abeta(1-42) clearance by extracellular proteolysis; treatment with HCT-1026 or fenofibrate (esters of flurbiprofen and fenobric acid) inhibited clearance of Abeta(1-40) and Abeta(1-42).	fenofibric acid	44-59	amyloid beta precursor protein	Homo sapiens	81-86
20075570-5	2010	Fenofibric acid, a fenofibrate metabolite, inhibited URAT1 to an extent similar to that observed with benzbromarone and losartan.	fenofibric acid	0-15	solute carrier family 22 member 12	Homo sapiens	53-58
20075570-6	2010	CONCLUSION: Fenofibrate decreased serum uric acid levels by increasing its urinary excretion, most likely through the inhibition of URAT1 by fenofibric acid, its major metabolite.	fenofibric acid	141-156	solute carrier family 22 member 12	Homo sapiens	132-137
19702658-9	2009	Treatment of N2a cells with flurbiprofen or fenofibric acid selectively enhanced Abeta(1-42) clearance by extracellular proteolysis; treatment with HCT-1026 or fenofibrate (esters of flurbiprofen and fenobric acid) inhibited clearance of Abeta(1-40) and Abeta(1-42).	fenofibric acid	44-59	amyloid beta precursor protein	Homo sapiens	238-243
19702658-9	2009	Treatment of N2a cells with flurbiprofen or fenofibric acid selectively enhanced Abeta(1-42) clearance by extracellular proteolysis; treatment with HCT-1026 or fenofibrate (esters of flurbiprofen and fenobric acid) inhibited clearance of Abeta(1-40) and Abeta(1-42).	fenofibric acid	44-59	amyloid beta precursor protein	Homo sapiens	238-243
19445040-5	2009	Unexpectedly, fenofibric acid lowered apoA-I medium concentrations in both cell lines, which could not be explained by a lack of PPAR transactivation or a lack of retinoid-X-receptor a activation.	fenofibric acid	14-29	apolipoprotein A1	Homo sapiens	38-44
19534718-6	2009	The EC monolayer permeability increase induced by 4 h of OGD was significantly restricted after treatment with the PPAR-alpha agonist fenofibric acid (FA) 24 h before or at the onset of OGD.	fenofibric acid	134-149	peroxisome proliferator activated receptor alpha	Mus musculus	115-125
18325492-5	2008	Wild-type AKR1B10-catalyzed carbonyl reduction follows pure non-competitive inhibition kinetics using zopolrestat, EBPC or sorbinil, whereas fenofibrate, Wy 14,643, ciprofibrate and fenofibric acid follow mixed non-competitive inhibition kinetics.	fenofibric acid	182-197	aldo-keto reductase family 1 member B10	Homo sapiens	10-17
19929038-1	2009	Fenofibric acid activates peroxisome proliferator-activated receptor alpha to modify fatty acid and lipid metabolism.	fenofibric acid	0-15	peroxisome proliferator activated receptor alpha	Homo sapiens	26-74
21291802-6	2009	RESULTS: Fenofibric acid + low-dose statin increased HDL-C (18.1% vs. 7.4%) and reduced TG (-43.9% vs. -16.8%) versus low-dose statin monotherapy and reduced LDL-C (-33.1% vs. -5.1%) versus fenofibric acid monotherapy (P <.001 for all).	fenofibric acid	9-24	component of oligomeric golgi complex 2	Homo sapiens	158-163
21291802-7	2009	Fenofibric acid + moderate-dose statin increased HDL-C (17.5% vs. 8.7%) and reduced TG (-42.0% vs. -23.7%) versus moderate-dose statin monotherapy and reduced LDL-C (-34.6% vs. -5.1%) versus fenofibric acid monotherapy (P <.001 for all).	fenofibric acid	0-15	component of oligomeric golgi complex 2	Homo sapiens	159-164
18455211-4	2008	In subsequent in vitro studies, we observed increased expression of ALT1 protein and mRNA in human hepatocytes after treatment with fenofibric acid.	fenofibric acid	132-147	glutamic--pyruvic transaminase	Homo sapiens	68-72
18325492-8	2008	The reaction of the mutant AKR1B10 is inhibited by fenofibric acid, but manifests pure non-competitive inhibition kinetics that are different from those demonstrated for the wild-type enzyme.	fenofibric acid	51-66	aldo-keto reductase family 1 member B10	Homo sapiens	27-34
18245819-7	2008	Fenofibric acid (FA) reduced PCSK9 protein content in immortalized human hepatocytes (IHH) as well as its cellular secretion.	fenofibric acid	0-15	proprotein convertase subtilisin/kexin type 9	Homo sapiens	29-34
16339839-7	2006	Plasma concentration of fenofibric acid was similar to the EC50 for activation of PPAR-alpha in vitro and to maximal concentrations achieved in clinical use.	fenofibric acid	24-39	peroxisome proliferator activated receptor alpha	Sus scrofa	82-92
17533223-4	2007	FF, a prodrug, was a more potent inhibitor of SR-BI than an activator of peroxisome proliferator-activated receptor alpha, a target of its active fenofibric acid (FFA) derivative.	fenofibric acid	146-161	peroxisome proliferator activated receptor alpha	Homo sapiens	73-121
17533223-4	2007	FF, a prodrug, was a more potent inhibitor of SR-BI than an activator of peroxisome proliferator-activated receptor alpha, a target of its active fenofibric acid (FFA) derivative.	fenofibric acid	163-166	peroxisome proliferator activated receptor alpha	Homo sapiens	73-121
17314201-5	2007	hOAT3-mediated sitagliptin uptake was inhibited by probenecid, ibuprofen, furosemide, fenofibric acid, quinapril, indapamide, and cimetidine with IC50 values of 5.6, 3.7, 1.7, 2.2, 6.2, 11, and 79 microM, respectively.	fenofibric acid	86-101	solute carrier family 22 member 8	Homo sapiens	0-5
17022944-0	2006	Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro.	fenofibric acid	99-114	aldehyde oxidase 1	Homo sapiens	0-18
17022944-4	2006	Adiponectin and fenofibric acid activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and both suppress AOX1 protein and this is blocked by the PPAR-alpha antagonist RU486.	fenofibric acid	16-31	peroxisome proliferator activated receptor alpha	Homo sapiens	41-89
17022944-4	2006	Adiponectin and fenofibric acid activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and both suppress AOX1 protein and this is blocked by the PPAR-alpha antagonist RU486.	fenofibric acid	16-31	peroxisome proliferator activated receptor alpha	Homo sapiens	91-101
17022944-4	2006	Adiponectin and fenofibric acid activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and both suppress AOX1 protein and this is blocked by the PPAR-alpha antagonist RU486.	fenofibric acid	16-31	aldehyde oxidase 1	Homo sapiens	121-125
17022944-4	2006	Adiponectin and fenofibric acid activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and both suppress AOX1 protein and this is blocked by the PPAR-alpha antagonist RU486.	fenofibric acid	16-31	peroxisome proliferator activated receptor alpha	Homo sapiens	161-171
16023994-5	2005	In contrast, fenofibric acid reduces AdipoR1 whereas hepatotoxic troglitazone upregulates AdipoR1 protein in HepG2 cells.	fenofibric acid	13-28	adiponectin receptor 1	Homo sapiens	37-44
14982965-3	2004	In addition, [(3)H]NS-220 bound to the ligand-binding domain of human PPARalpha with a K(D) value of 1.85 x 10(-7) M. Fenofibric acid and bezafibrate showed weak agonist activity for PPARalpha (EC(50), 2-8 x 10(-5) M), with poor subtype selectivity.	fenofibric acid	118-133	peroxisome proliferator activated receptor alpha	Homo sapiens	70-79
15790930-0	2005	Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner.	fenofibric acid	0-15	apolipoprotein A1	Homo sapiens	58-76
15790930-0	2005	Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner.	fenofibric acid	0-15	ATP binding cassette subfamily A member 1	Homo sapiens	152-187
15790930-4	2005	METHODS AND RESULTS: Fenofibric acid was examined for the effect of increase of ABCA1 activity.	fenofibric acid	21-36	ATP binding cassette subfamily A member 1	Homo sapiens	80-85
15790930-8	2005	CONCLUSIONS: Fenofibric acid increased transcription of ABCA1 gene in a liver X receptor-dependent manner.	fenofibric acid	13-28	ATP binding cassette subfamily A member 1	Homo sapiens	56-61
15685545-5	2005	The influence of HCV core protein on PPARalpha mRNA expression was analyzed in vitro by real-time PCR in HCV core-expressing HepG2 cells activated with the PPARalpha ligand fenofibric acid.	fenofibric acid	173-188	peroxisome proliferator activated receptor alpha	Homo sapiens	37-46
15685545-5	2005	The influence of HCV core protein on PPARalpha mRNA expression was analyzed in vitro by real-time PCR in HCV core-expressing HepG2 cells activated with the PPARalpha ligand fenofibric acid.	fenofibric acid	173-188	peroxisome proliferator activated receptor alpha	Homo sapiens	156-165
15771232-7	2005	Significant increases (3- to 6-fold) in amodiaquine N-deethylase (a functional probe for CYP2C8 activity) also were observed with clofibric acid, fenofibric acid, and rifampin, in agreement with the mRNA finding.	fenofibric acid	146-161	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	89-95
15771232-12	2005	CONCLUSIONS: In human hepatocytes, both fenofibric acid and clofibric acid are inducers of CYP3A4 and CYP2C8.	fenofibric acid	40-55	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-97
15771232-12	2005	CONCLUSIONS: In human hepatocytes, both fenofibric acid and clofibric acid are inducers of CYP3A4 and CYP2C8.	fenofibric acid	40-55	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	102-108
15169608-7	2004	Avasimibe, fluvastatin, and PPARalpha agonists (fenofibric acid and Wy-14643) significantly reduced, in a concentration-dependent manner, MMP-9 protein (up to 67 +/- 5% for fenofibric acid).	fenofibric acid	48-63	peroxisome proliferator activated receptor alpha	Homo sapiens	28-37
15169608-7	2004	Avasimibe, fluvastatin, and PPARalpha agonists (fenofibric acid and Wy-14643) significantly reduced, in a concentration-dependent manner, MMP-9 protein (up to 67 +/- 5% for fenofibric acid).	fenofibric acid	48-63	matrix metallopeptidase 9	Homo sapiens	138-143
15169608-7	2004	Avasimibe, fluvastatin, and PPARalpha agonists (fenofibric acid and Wy-14643) significantly reduced, in a concentration-dependent manner, MMP-9 protein (up to 67 +/- 5% for fenofibric acid).	fenofibric acid	173-188	peroxisome proliferator activated receptor alpha	Homo sapiens	28-37
15169608-7	2004	Avasimibe, fluvastatin, and PPARalpha agonists (fenofibric acid and Wy-14643) significantly reduced, in a concentration-dependent manner, MMP-9 protein (up to 67 +/- 5% for fenofibric acid).	fenofibric acid	173-188	matrix metallopeptidase 9	Homo sapiens	138-143
14613528-0	2003	Induction of Tissue Factor Expression in Endothelial Cells by Basic Fibroblast Growth Factor and its Modulation by Fenofibric acid.	fenofibric acid	115-130	coagulation factor III, tissue factor	Homo sapiens	13-26
14698041-5	2004	We tested whether gemfibrozil, fenofibrate, fenofibric acid, and bezafibrate inhibit Pgp in vitro using a calcein acetoxymethylester (calcein-AM) uptake assay and confocal laser scanning microscopy with bodipy-verapamil as substrate in L-MDR1 cells, which overexpress human Pgp.	fenofibric acid	44-59	ATP binding cassette subfamily B member 1	Homo sapiens	85-88
14613528-13	2003	Fenofibric acid, an agonist ligand for the peroxisome proliferator activated receptor-alpha, reduced basal and bFGF stimulated TF expression.	fenofibric acid	0-15	peroxisome proliferator activated receptor alpha	Homo sapiens	43-91
14613528-13	2003	Fenofibric acid, an agonist ligand for the peroxisome proliferator activated receptor-alpha, reduced basal and bFGF stimulated TF expression.	fenofibric acid	0-15	fibroblast growth factor 2	Homo sapiens	111-115
14613528-13	2003	Fenofibric acid, an agonist ligand for the peroxisome proliferator activated receptor-alpha, reduced basal and bFGF stimulated TF expression.	fenofibric acid	0-15	coagulation factor III, tissue factor	Homo sapiens	127-129
12644596-6	2003	In HuH7 human hepatoma cells, the PON-1 secreted enzymatic activity and mRNA levels were increased by fenofibric acid (approximately 70%) and decreased by several statins (approximately 50%).	fenofibric acid	102-117	paraoxonase 1	Homo sapiens	34-39
12790802-9	2003	Furthermore, downregulation of PTP-LAR by fenofibric acid was demonstrated in rat FaO hepatoma cells in vitro, indicating that the observed regulation of PTP-LAR by fenofibrate and Wy-14643 in vivo is mediated as a direct effect of the PPAR agonists on the hepatocytes.	fenofibric acid	42-57	protein tyrosine phosphatase, non-receptor type 1	Rattus norvegicus	31-34
12790802-9	2003	Furthermore, downregulation of PTP-LAR by fenofibric acid was demonstrated in rat FaO hepatoma cells in vitro, indicating that the observed regulation of PTP-LAR by fenofibrate and Wy-14643 in vivo is mediated as a direct effect of the PPAR agonists on the hepatocytes.	fenofibric acid	42-57	protein tyrosine phosphatase, receptor type, F	Rattus norvegicus	35-38
12790802-9	2003	Furthermore, downregulation of PTP-LAR by fenofibric acid was demonstrated in rat FaO hepatoma cells in vitro, indicating that the observed regulation of PTP-LAR by fenofibrate and Wy-14643 in vivo is mediated as a direct effect of the PPAR agonists on the hepatocytes.	fenofibric acid	42-57	protein tyrosine phosphatase, non-receptor type 1	Rattus norvegicus	154-157
12790802-9	2003	Furthermore, downregulation of PTP-LAR by fenofibric acid was demonstrated in rat FaO hepatoma cells in vitro, indicating that the observed regulation of PTP-LAR by fenofibrate and Wy-14643 in vivo is mediated as a direct effect of the PPAR agonists on the hepatocytes.	fenofibric acid	42-57	protein tyrosine phosphatase, receptor type, F	Rattus norvegicus	158-161
12790802-9	2003	Furthermore, downregulation of PTP-LAR by fenofibric acid was demonstrated in rat FaO hepatoma cells in vitro, indicating that the observed regulation of PTP-LAR by fenofibrate and Wy-14643 in vivo is mediated as a direct effect of the PPAR agonists on the hepatocytes.	fenofibric acid	42-57	peroxisome proliferator activated receptor alpha	Rattus norvegicus	236-240
12810707-4	2003	Incubation of human hepatocytes or hepatoblastoma HepG2 and Huh7 cells with synthetic PPAR alpha agonists, fenofibric acid, or Wy 14643 resulted in an increase of UGT2B4 mRNA levels.	fenofibric acid	107-122	UDP glucuronosyltransferase family 2 member B4	Homo sapiens	163-169
12954370-0	2003	Dilazep and fenofibric acid inhibit MCP-1 mRNA expression in glycoxidized LDL-stimulated human endothelial cells.	fenofibric acid	12-27	C-C motif chemokine ligand 2	Homo sapiens	36-41
12954370-3	2003	Both 10 microg/ml dilazep and 100 microM fenofibric acid abrogated MCP-1 mRNA expression.	fenofibric acid	41-56	C-C motif chemokine ligand 2	Homo sapiens	67-72
11418601-4	2001	In addition, apolipoprotein CIII mRNA was decreased by both fenofibric acid and compound 1 in rat hepatocytes.	fenofibric acid	60-75	apolipoprotein C3	Rattus norvegicus	13-32
10498661-5	1999	After fenofibric acid treatment, we show a parallel increase in apoAII and core protein secretion, this effect being abolished by brefeldin A.	fenofibric acid	6-21	apolipoprotein A2	Homo sapiens	64-70
10456614-3	1999	Oncostatin-M- and interleukin-6-induced fibrinogen release was inhibited in a dose-dependent manner by ciprofibrate and, to lesser extent, by bezafibrate, fenofibric acid and clofibric acid.	fenofibric acid	155-170	oncostatin M	Rattus norvegicus	0-13
10456614-3	1999	Oncostatin-M- and interleukin-6-induced fibrinogen release was inhibited in a dose-dependent manner by ciprofibrate and, to lesser extent, by bezafibrate, fenofibric acid and clofibric acid.	fenofibric acid	155-170	interleukin 6	Homo sapiens	18-31
10456614-3	1999	Oncostatin-M- and interleukin-6-induced fibrinogen release was inhibited in a dose-dependent manner by ciprofibrate and, to lesser extent, by bezafibrate, fenofibric acid and clofibric acid.	fenofibric acid	155-170	fibrinogen beta chain	Homo sapiens	40-50
12006402-11	2002	Fenofibric acid, an agonist ligand for the peroxisome proliferator-activated receptor-alpha, inhibited basal and bFGF-stimulated PAI-1 expression.	fenofibric acid	0-15	peroxisome proliferator activated receptor alpha	Homo sapiens	43-91
12006402-11	2002	Fenofibric acid, an agonist ligand for the peroxisome proliferator-activated receptor-alpha, inhibited basal and bFGF-stimulated PAI-1 expression.	fenofibric acid	0-15	fibroblast growth factor 2	Homo sapiens	113-117
12006402-11	2002	Fenofibric acid, an agonist ligand for the peroxisome proliferator-activated receptor-alpha, inhibited basal and bFGF-stimulated PAI-1 expression.	fenofibric acid	0-15	serpin family E member 1	Homo sapiens	129-134
14727988-1	2002	The prodrug fenofibrate, a synthetic phenoxy-isobutyric acid derivative, is rapidly hydrolyzed in vivo to form fenofibric acid, which alters plasma lipid levels by activating the peroxisome proliferator-activated receptor alpha.	fenofibric acid	111-126	peroxisome proliferator activated receptor alpha	Homo sapiens	179-227
12481201-2	2002	Its active metabolite, fenofibric acid, is responsible for the primary pharmacodynamic effects of the drug: reductions in total plasma cholesterol, low density lipoprotein cholesterol, triglycerides, and very low-density lipoprotein concentrations and increases in high-density lipoprotein cholesterol and apolipoproteins AI and AII concentrations.	fenofibric acid	23-38	NLR family pyrin domain containing 3	Homo sapiens	329-332
11208678-6	2001	Fenofibric acid, WY14643, and GW2331 inhibited TF mRNA upregulation after stimulation of THP-1 cells with lipopolysaccharide or interleukin-1ss.	fenofibric acid	0-15	coagulation factor III, tissue factor	Homo sapiens	47-49
11208678-7	2001	In primary human monocytes and macrophages, the lipopolysaccharide- or interleukin-1ss-mediated induction of TF activity was also inhibited by fenofibric acid, WY14643, or GW2331.	fenofibric acid	143-158	coagulation factor III, tissue factor	Homo sapiens	109-111
10364093-7	1999	In contrast, both fenofibric acid and gemfibrozil markedly decreased PAI-1 transcription and secretion from HUVECs and EA.hy926 cells.	fenofibric acid	18-33	serpin family E member 1	Homo sapiens	69-74